Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey. more
Time Frame | CLDX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.11% | -3.39% | -3.47% |
1-Month Return | 6.48% | -3.25% | -0.29% |
3-Month Return | -40.69% | -11.61% | 4.5% |
6-Month Return | -28.39% | -5.89% | 6.91% |
1-Year Return | -32.65% | 2.65% | 23.79% |
3-Year Return | -36.55% | 0.56% | 28.43% |
5-Year Return | 993.39% | 34.63% | 83.64% |
10-Year Return | -91.21% | 94.78% | 185.94% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 3.57M | 7.42M | 4.65M | 2.36M | 6.88M | [{"date":"2019-12-31","value":48.17,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":62.7,"profit":true},{"date":"2022-12-31","value":31.77,"profit":true},{"date":"2023-12-31","value":92.79,"profit":true}] |
Cost of Revenue | 42.67M | 42.53M | 3.07M | 1.40M | 3.01M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":99.68,"profit":true},{"date":"2021-12-31","value":7.19,"profit":true},{"date":"2022-12-31","value":3.28,"profit":true},{"date":"2023-12-31","value":7.05,"profit":true}] |
Gross Profit | (39.10M) | (35.12M) | 1.58M | 957.00K | 3.88M | [{"date":"2019-12-31","value":-1009.01,"profit":false},{"date":"2020-12-31","value":-906.22,"profit":false},{"date":"2021-12-31","value":40.85,"profit":true},{"date":"2022-12-31","value":24.7,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (1094.29%) | (473.39%) | 34.04% | 40.60% | 56.30% | [{"date":"2019-12-31","value":-1943.74,"profit":false},{"date":"2020-12-31","value":-840.86,"profit":false},{"date":"2021-12-31","value":60.46,"profit":true},{"date":"2022-12-31","value":72.12,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 58.10M | 56.99M | 73.80M | 109.45M | 161.43M | [{"date":"2019-12-31","value":35.99,"profit":true},{"date":"2020-12-31","value":35.3,"profit":true},{"date":"2021-12-31","value":45.72,"profit":true},{"date":"2022-12-31","value":67.8,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (55.03M) | (63.35M) | (71.24M) | (115.23M) | (154.54M) | [{"date":"2019-12-31","value":-5503100000,"profit":false},{"date":"2020-12-31","value":-6335400000,"profit":false},{"date":"2021-12-31","value":-7124300000,"profit":false},{"date":"2022-12-31","value":-11523400000,"profit":false},{"date":"2023-12-31","value":-15454200000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (50.88M) | (60.95M) | (70.74M) | (112.33M) | (141.43M) | [{"date":"2019-12-31","value":-5087800000,"profit":false},{"date":"2020-12-31","value":-6094700000,"profit":false},{"date":"2021-12-31","value":-7073800000,"profit":false},{"date":"2022-12-31","value":-11232500000,"profit":false},{"date":"2023-12-31","value":-14142900000,"profit":false}] |
Income Taxes | (506.00K) | (1.17M) | (227.00K) | 10.46M | 2.84M | [{"date":"2019-12-31","value":-4.84,"profit":false},{"date":"2020-12-31","value":-11.16,"profit":false},{"date":"2021-12-31","value":-2.17,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":27.16,"profit":true}] |
Income After Taxes | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (50.88M) | (59.78M) | (70.51M) | (112.33M) | (124.61M) | [{"date":"2019-12-31","value":-5087800000,"profit":false},{"date":"2020-12-31","value":-5978000000,"profit":false},{"date":"2021-12-31","value":-7051100000,"profit":false},{"date":"2022-12-31","value":-11232500000,"profit":false},{"date":"2023-12-31","value":-12461000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (50.37M) | (59.78M) | (70.51M) | (122.78M) | (141.43M) | [{"date":"2019-12-31","value":-5037200000,"profit":false},{"date":"2020-12-31","value":-5978000000,"profit":false},{"date":"2021-12-31","value":-7051100000,"profit":false},{"date":"2022-12-31","value":-12278300000,"profit":false},{"date":"2023-12-31","value":-14142900000,"profit":false}] |
EPS (Diluted) | (3.63) | (2.14) | (1.64) | (2.21) | (2.91) | [{"date":"2019-12-31","value":-363,"profit":false},{"date":"2020-12-31","value":-214,"profit":false},{"date":"2021-12-31","value":-164,"profit":false},{"date":"2022-12-31","value":-221,"profit":false},{"date":"2023-12-31","value":-291,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CLDX | |
---|---|
Cash Ratio | 23.56 |
Current Ratio | 24.27 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CLDX | |
---|---|
ROA (LTM) | -19.73% |
ROE (LTM) | -29.84% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CLDX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.05 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.95 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CLDX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 165.06 |
P/B | 2.20 |
Price/FCF | NM |
EV/R | 97.70 |
EV/Ebitda | NM |
PEG | NM |
Celldex Therapeutics Inc (CLDX) share price today is $24.918
Yes, Indians can buy shares of Celldex Therapeutics Inc (CLDX) on Vested. To buy Celldex Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CLDX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Celldex Therapeutics Inc (CLDX) via the Vested app. You can start investing in Celldex Therapeutics Inc (CLDX) with a minimum investment of $1.
You can invest in shares of Celldex Therapeutics Inc (CLDX) via Vested in three simple steps:
The 52-week high price of Celldex Therapeutics Inc (CLDX) is $53.18. The 52-week low price of Celldex Therapeutics Inc (CLDX) is $22.93.
The price-to-earnings (P/E) ratio of Celldex Therapeutics Inc (CLDX) is
The price-to-book (P/B) ratio of Celldex Therapeutics Inc (CLDX) is 2.20
The dividend yield of Celldex Therapeutics Inc (CLDX) is 0.00%
The market capitalization of Celldex Therapeutics Inc (CLDX) is $1.65B
The stock symbol (or ticker) of Celldex Therapeutics Inc is CLDX